Reference is made to the stock exchange announcement fromSoftOx Solutions AS (the "Company") on29 December 2021 regarding the Company's extraordinary general meeting resolving to issue 259,403 new shares in the Company against a set-off ofNOK 9,999,985.65 of Almhaug Bolig AS' claim against the Company under a loan agreement dated13 October 2021 . The share capital increase pertaining to the debt conversion ofNOK 5,188.06 divided on 259,403 shares has today been registered in theNorwegian Register ofBusiness Enterprises (Nw: Foretaksregisteret). Following the share capital increase, the new share capital in the Company isNOK 206,857.42 divided into 10,342,871 shares, each with a nominal value ofNOK 0.02 . The new shares will be listed and tradable on Euronext Growth Oslo from issuance in theCentral Securities Depository (VPS). For further information, please contact: CEOGeir Almås ofSoftOx Solutions AS , or CFOKristine Rød ofSoftOx Solutions AS Mail: ir@soft-ox.com Mobile: (+47) 948 59 599 AboutSoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based inOslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com
Click here for more information
© Oslo Bors ASA, source